Logo
P

Precigen

113 employees

Precigen: Advancing Medicine with Precision™ Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

Investor insights

Funding rounds participated in

$79M sweet spot round size

Investor type

Public Company

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Funding rounds raised

Total raised

$79M

from 2 investors over 1 rounds

P

Precigen raised $79M on January 27, 2025

Investors: Patient Capital Management and + 1 Other investor

FAQ